Afghanistan vs Nepal: Average cost of drugs for extensively drug-resistant tuberculosis
Afghanistan
2,000 constant 2022 US$
in 2024
Nepal
2,853 constant 2022 US$
in 2024
Afghanistan rank
24th
Nepal rank
21st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Afghanistan
- Nepal
How they compare
Nepal currently reports 2,853 constant 2022 US$ against 2,000 constant 2022 US$ in Afghanistan, a difference of 853 constant 2022 US$.
That makes Nepal's figure about 1.4 times Afghanistan's.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Nepal ahead.
Afghanistan ranks 24th and Nepal ranks 21st of 56 countries.
Nepal has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,350 constant 2022 US$ | 2,811 constant 2022 US$ | 461 constant 2022 US$ | Nepal |
| 2020s | 1,900 constant 2022 US$ | 2,995 constant 2022 US$ | 1,095 constant 2022 US$ | Nepal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Afghanistan or Nepal?
- Nepal, at 2,853 constant 2022 US$ against 2,000 constant 2022 US$ in Afghanistan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Afghanistan and Nepal?
- 853 constant 2022 US$, with Nepal ahead.
- How many years of comparable data are there for Afghanistan and Nepal?
- 7 years are reported by both, from 2018 to 2024.
- How do Afghanistan and Nepal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Afghanistan ranks 24th and Nepal ranks 21st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.